文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

左西孟旦对接受体外循环冠状动脉旁路移植术的低射血分数患者低心输出量综合征的影响:LICORN随机临床试验

Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

在法国13个心脏外科中心开展的随机双盲安慰剂对照试验,纳入左心室射血分数≤40%且接受体外循环冠状动脉旁路移植术的患者,比较术前24小时输注左西孟旦0.1 µg/kg/min与安慰剂的疗效。主要复合终点在左西孟旦组87例(52%)、安慰剂组101例(61%)发生,校正中心效应后绝对风险差-7%(95%CI -17%至3%;P=0.15),无显著差异。结论不支持左西孟旦用于该适应证。

要点

  • 左西孟旦组主要复合终点发生率为52%,安慰剂组为61%,绝对风险差-7%(95%CI -17%至3%;P=0.15)。
  • 预设亚组分析未发现与射血分数<30%、手术类型或术前使用β受体阻滞剂、主动脉内球囊反搏或儿茶酚胺存在交互作用。
  • 低血压(57% vs 48%)、心房颤动(50% vs 40%)及其他不良事件在两组间无显著差异。

核心结论

  • 在低射血分数接受体外循环冠状动脉旁路移植术的患者中,左西孟旦与安慰剂相比在延长儿茶酚胺输注、使用左心室机械辅助装置或肾脏替代治疗的复合终点上无显著差异。
  • 这些发现不支持左西孟旦用于该适应证。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在法国13个心脏外科中心开展。
  • 纳入左心室射血分数≤40%并计划行单纯或联合体外循环冠状动脉旁路移植术的患者,2013年6月至2015年5月入组,随访6个月(末次随访2015年11月30日)。
  • 患者被分配接受左西孟旦0.1 µg/kg/min(n=167)或安慰剂(n=168)24小时输注,于麻醉诱导后开始。
  • 共336例随机患者(平均年龄68岁;女性16%),333例完成试验。

主要发现

  • 主要复合终点在左西孟旦组87例(52%)发生,安慰剂组101例(61%)发生,校正中心效应后绝对风险差-7%(95%CI -17%至3%;P=0.15)。
  • 预设亚组分析未发现与射血分数<30%、手术类型、术前使用β受体阻滞剂、主动脉内球囊反搏或儿茶酚胺存在交互作用。
  • 低血压发生率左西孟旦组57% vs 安慰剂组48%,心房颤动左西孟旦组50% vs 安慰剂组40%,其他不良事件在两组间无显著差异。

关键数值与推荐

  • 主要复合终点包括:研究药物开始后48小时需要儿茶酚胺输注、研究药物开始后96小时需要左心室机械辅助装置或术前已置入装置者无法脱离、或术后任何时间需要肾脏替代治疗。
  • 研究假设左西孟旦较安慰剂降低该复合终点发生率15%。

临床怎么用

  • 原文结论为这些发现不支持左西孟旦用于该适应证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Low cardiac output syndrome after cardiac surgery is associated with high morbidity and mortality in patients with impaired left ventricular function. OBJECTIVE: To assess the ability of preoperative levosimendan to prevent postoperative low cardiac output syndrome. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted in 13 French cardiac surgical centers. Patients with a left ventricular ejection fraction less than or equal to 40% and scheduled for isolated or combined coronary artery bypass grafting with cardiopulmonary bypass were enrolled from June 2013 until May 2015 and followed during 6 months (last follow-up, November 30, 2015). INTERVENTIONS: Patients were assigned to a 24-hour infusion of levosimendan 0.1 µg/kg/min (n = 167) or placebo (n = 168) initiated after anesthetic induction. MAIN OUTCOMES AND MEASURES: Composite end point reflecting low cardiac output syndrome with need for a catecholamine infusion 48 hours after study drug initiation, need for a left ventricular mechanical assist device or failure to wean from it at 96 hours after study drug initiation when the device was inserted preoperatively, or need for renal replacement therapy at any time postoperatively. It was hypothesized that levosimendan would reduce the incidence of this composite end point by 15% in comparison with placebo. RESULTS: Among 336 randomized patients (mean age, 68 years; 16% women), 333 completed the trial. The primary end point occurred in 87 patients (52%) in the levosimendan group and 101 patients (61%) in the placebo group (absolute risk difference taking into account center effect, -7% [95% CI, -17% to 3%]; P = .15). Predefined subgroup analyses found no interaction with ejection fraction less than 30%, type of surgery, and preoperative use of β-blockers, intra-aortic balloon pump, or catecholamines. The prevalence of hypotension (57% vs 48%), atrial fibrillation (50% vs 40%), and other adverse events did not significantly differ between levosimendan and placebo. CONCLUSIONS AND RELEVANCE: Among patients with low ejection fraction who were undergoing coronary artery bypass grafting with cardiopulmonary bypass, levosimendan compared with placebo did not result in a significant difference in the composite end point of prolonged catecholamine infusion, use of left ventricular mechanical assist device, or renal replacement therapy. These findings do not support the use of levosimendan for this indication. TRIAL REGISTRATION: EudraCT Number: 2012-000232-25; clinicaltrials.gov Identifier: NCT02184819.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Cholley B, Caruba T, Grosjean S, et al. Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial. JAMA. 2017. PMID: 28787507. doi:10.1001/jama.2017.9973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。